The evolving medicines model
âThe very factors that drive the success of the generic market in the UK may be under threatâ
Future of Pharmaceuticals 2019
It takes an average of 10-15 years to get a drug to market, but how will artificial intelligence make a difference in the early development stages of drugs? Our Future of Pharmaceuticals special report, published in The Times, explores how the industry is moving to be part of open, learning communities where collaboration is at the forefront. It examines why pharmaceuticals is lagging behind in exploiting technological possibilities and whether we should redefine ageing as a disease. It looks at antimicrobial resistance and what antibiotics are really worth. Also featured is an infographic analysing the global rise of generic drugs.
In association with
In this report
-
What are new antibiotics really worth?
Antimicrobial resistance is one of the greatest challenges of our time, but few new antibiotics are currently in development. The NHS is testing the worldâs first subscription-style payment model in an attempt to change this
-
India: a global pharma powerhouse
Indiaâs economy may be struggling, but its pharmaceutical industry is booming, thanks to initiatives to improve domestic access to medicine and a solid export market. But can such growth continue?
-
Should we treat ageing like a disease?
Could reclassifying 'ageing' as a disease or condition alleviate the suffering that accompanies getting older?
Sponsored content
-
Drug development goes digital
Strategic use of patient data is signalling a bright future for drug development in the face of unprecedented global healthcare challenges
-
Big data can help rescue healthcare
Innovative use of transformative big data can bring medicines to those in need, improve healthcare systems and empower patients
-
Tackling the next frontier of liver disease
An innovative pharma company has set its sights on treating non-viral liver diseases
-
Q&A: Connecting the dots along the pharma value chain
Industry leaders hold the âmagic wandâ to empower their talent to supercharge the potential of a patient-centric pharma value chain, says Louis Hendriks, founder and initiator of Global Value Web
-
Acino and Quay steer new course for contract development and manufacturing
As the era of blockbuster drugs comes to an end, pharma is moving towards drugs that are increasingly complex and made for small patient populations, creating opportunities and challenges for contract development and manufacturing organisations (CDMOs)
-
Combating Cancer 2020
3,600 lives in the UK could be lost to the four main cancers over the next five years due to delays caused by COVID-19. Our Combating Cancer special report, published in The Times, explores why COVID has made it harder than ever to treat and diagnose cancer, dietary advice, and more. The featured infographic examines how where you live can impact your risk of getting cancer and the care you can expect if you do.
-
Business Growth & Recovery 2020
Our Business Recovery & Growth special report, published in The Times, focuses on providing business leaders with positive and practical guidance to prepare for a resilient and stronger 2021. It features content on pivoting to eCommerce, new ways of engaging with customers, cross-border transactions and borderless transfers, and the cruciality of supply-chain sustainability. The featured infographic explores what the outlook really is for business recovery and COVID-19.
-
The Future CMO 2020
Our Future CMO special report, published in The Times, features articles on combating fake news, upcoming Christmas campaigns, celebrity founders and branding, and more. It features an infographic on the changing evolution of the advertising landscape from traditional to digital.
-
Climate Change 2020
Our Climate Change special report, published in The Times, explores innovative ways to offset carbon emissions, staying profitable as a B corp, and the environmental cost of going digital. It also looks at which business leaders are lobbying for real action. The infographic examines how big your businessâs carbon footprint is and the impact of remote working.Â